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ess: icerveri@smatteo.pSummary Chronic obstructive pulmonary disease (COPD) exacerbations could
represent an opportunity for pro-active COPD management rather than mere
treatment if previously unknown disease is discovered; the extent of underdiagnosis
and undertreatment of COPD in patients attending an emergency department (ED)
with an exacerbation is not known.
During 2002, we recalled 131 COPD patients in stable conditions, 4–8 weeks after
they had attended the ED or been discharged from our University Hospital (North-
West of Italy). Information on diagnosis and management prior to the ED attendance
were collected; spirometry and arterial blood gas analyses were performed.
One-third of patients had never been diagnosed and treated even though 83% of
them had moderate-to-very-severe COPD and about 30% already had respiratory
failure. Only 20% had received information on the nature of the disease and none had
received a written action plan. Only 60% were receiving long-acting bronchodilators
and 41% of patients with respiratory failure were receiving long-term oxygen. A
substantial number of undiagnosed and untreated patients with moderate-to-very-
severe COPD came to our attention through an exacerbation. This enforces the
importance of exacerbations as the starting point of pro-active COPD management
and of the ED as a valuable sentinel to identify this subset of patients.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
2 502611;
v.it (I. Cerveri).Introduction
Several studies and recent expert panels have
emphasized the underreporting and underrecogni-
tion of COPD.1–4 The objectives of the GOLDed.
ARTICLE IN PRESS
Exacerbations as a pro-active COPD management 1569project are
’ ’
to increase awareness of COPD and
decrease mortality from this disease’’.5 The Na-
tional Lung Health Education Program has sug-
gested that primary care physicians should ensure
that screening spirometry is done in patients at
high risk.6 Recently it has been found that routine
spirometry in patients admitted to a general
medicine service may be useful for identifying
COPD patients and possibly for initiating counseling
or appropriate medical treatment.7
In the recent years, much attention has been
paid to COPD exacerbations, their treatment and
their consequences on the disease progression8;
however, the importance of exacerbations in
becoming the starting point of pro-active COPD
management has not been acknowledged. Emer-
gency department (ED) attendance because of an
exacerbation of respiratory symptoms could repre-
sent an opportunity to consider intervention if
previously unknown disease is discovered, particu-
larly in patient populations who underuse primary
care physicians. Much recent evidence has shown
that the available treatments are able to influence
health-outcome measures related to quality of life,
such as the severity of dyspnea, exercise capacity,
and exacerbations even in the most severe
patients.9–11
The extent of previous underdiagnosis and under-
treatment in moderate-to-very-severe COPD pa-
tients attending an ED because of an exacerbation
of respiratory symptoms is unknown. The aims of
our study were: (1) to evaluate how many COPD
patients come to attention through an exacerbation
requiring the ED attendance; (2) to evaluate the
extent of undertreatment prior to the ED atten-
dance; (3) to create and propose a novel approach
for the management of patients with exacerbations
of COPD after the discharge from the ED.Materials and methods
Patients and study design
During 2002, 244 patients attended our ED because
of increased dyspnea and sputum production. The
diagnosis of exacerbation of COPD as the main
cause of these symptoms and their deterioration
was confirmed in 200 patients during the conse-
quent admission to hospital or, if the patient was
not hospitalized, in a subsequent specialistic out-
patient appointment, according to Rodriguez-
Rosin.12
When patients were confirmed to have suffered
from COPD exacerbations, they were given a letteraddressed to their GP explaining their clinical
status and proposing a novel approach of ongoing
pro-active management. We scheduled that the
patients had to be recalled 4–8 weeks after
attending the ED or after discharge from hospital,
when the exacerbation had resolved, in order to
answer specific questions on their clinical history,
previous diagnosis, treatment, educational mes-
sages, written action plans and on whether they
had undergone spirometry prior to the exacerba-
tion requiring the ED attendance. On the same day
the patients had to undergo spirometry and arterial
blood gas analysis. For the purpose of the present
study only patients able to reliably recall their
clinical history, co-operate well during the spiro-
metry and who had not had previous exacerbations
with admission to any hospital were included; the
number of excluded subjects and the specific
reasons for their exclusion are reported in Fig. 1.
Of the 131 eligible subjects only 13 were non-
responders because they lived far away from our
center.Classification of severity of COPD
A Vmax 22 system (SensorMedics, Yorba Linda, CA)
was used to measure lung function: forced expira-
tory volume in 1 s (FEV1) and forced vital capacity
(FVC) were determined according to the American
Thoracic Society criteria.13 Chronic airflow obstruc-
tion was defined as a FEV1/FVC ratio less than 70%.
5
The severity of COPD was classified on airflow
obstruction as measured by postbronchodilator
FEV1
5; predicted values were those of the European
Respiratory Society.14
Blood samples were drawn from the radial artery,
and gas tensions were measured by a Ciba Corning
855 gas analyzer (Ciba Corning Diagnostic,
Medfield, MA). Respiratory failure was defined
as a PaO2o60mmHg with or without PaCO24
45mmHg.5
The Medical Research Council (MRC) dyspnea
scale, modified according to Bestall et al.,15 was
incorporated into the questionnaire as a measure of
dyspnea severity: this scale ranges from 5 to 0 and
patients were considered to have dyspnea when the
score was 41.
Repeated exacerbations were defined according
to Burge and Wedzicha.8Statistical analysis
Group characteristics and lung function data were
compared by two-tailed unpaired Student’s t or w2
tests, whichever was appropriate. A probability
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cant. All values are reported as mean7SD.Results
Out of the 118 COPD patients included in our study
(M/F 96/22; age 74711 years) 63% had been
hospitalized after attending the ED, including one
patient who was admitted to the intensive care
unit.
At the time of our recall, all of them were in a
stable condition. The main patients’ characteristics
at the clinical examination and the distribution ofTable 1 Main patients’ characteristics.
Age (years) Without previous di
(n ¼ 33)
72713
Smoking habit
Persistent smokers 20 (60%)
Past smokers 13 (40%)
Never smokers 0 (0%)
COPD severity
GOLD stage 1 6 (18%)
GOLD stage 2 12 (36%)
GOLD stage 3 5 (15%)
GOLD stage 4 10 (30%)
Frequent exacerbations 0 (0%)
Respiratory failure 4 (12%)
Co-morbid conditions 9 (28%)
Figure 1 Number of patients not included in oupatients by COPD severity are reported in Table 1;
the majority of patients (83%) were in GOLD stage
41 and almost a half (46%) presented co-morbid
conditions. The mean values of lung function
and blood gas analysis parameters are reported in
Table 2.
Forty-four percent of the 118 COPD patients
reported that they had never undergone spirometry.Patients without a diagnosis of COPD prior to
the ED attendance
On our recall, 33 patients (28%) reported that they
had never been diagnosed as having COPD prior toagnosis With previous diagnosis
(n ¼ 85)
Whole group
(n ¼ 118)
7578 74711
29 (34%) 49 (41%)
55 (65%) 68 (58%)
1 (1%) 1 (1%)
14 (16%) 20 (17%)
20 (24%) 32 (27%)
20 (24%) 25 (21%)
31 (36%) 42 (35%)
20 (24%) 20 (17%)
29 (34%) 33 (28%)
45 (53%) 54 (46%)
r study and the reasons for their exclusion.
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Table 2 Mean values7SD of lung function and blood gas analysis parameters in the whole group and in the
different GOLD severity stages.
Stage 1 Stage 2 Stage 3 Stage 4 Total
FEV1
L 1.8970.39 1.6570.45 1.1170.21 0.9670.45 1.3570.57
% pred 8776 6779 4275 3872 54722
FVC
L 3.1570.66 2.7870.71 2.1670.51 2.1070.76 2.4670.78
%pred 111714 88714 63713 63721 77723
FEV1/FVC (%) 6176 6079 5378 46712 54713
PaO2 (mmHg) 7477 6979 6774 5779 65710
PaCO2 (mmHg) 3775 3675 3976 4576 4076
Exacerbations as a pro-active COPD management 1571the ED attendance. Eight percent of these patients
had never noted any chronic respiratory symptom;
44% reported chronic cough and phlegm, 44% also
suffered from dyspnea, and one patient reported
only dyspnea. Fifty-two percent of patients
who reported chronic respiratory symptoms to us
during the recall had never reported these
symptoms to their GP because they never visited
their GP or consulted him for other health
problems; three patients had undergone spirome-
try. Eighty-two percent were in GOLD stage 41;
none of them reported frequent exacerbations
prior to the ED attendance. Four patients had a
PaO2o60mmHg and none had a PaCO2445mmHg
(Table 1).Patients with a diagnosis of COPD prior to the
ED attendance
Out of the 85 patients (72%) with a previous
diagnosis of COPD the diagnosis had been made by
their GP for 43% of them and by a pulmonologist for
the remainder. The diagnosis was based on spiro-
metry in 75% of the patients diagnosed by a GP and
in 73% of the patients seen by a specialist. On our
recall, all the patients reported chronic respiratory
symptoms: 49% reported chronic cough and
phlegm, 48% also reported chronic dyspnea, three
patients suffered only from dyspnea. Fourteen
percent of these patients had never reported
their chronic respiratory symptoms to their GP;
74% had undergone spirometry. Eighty-five
percent of patients were in GOLD stage41. Twenty
percent reported frequent exacerbations prior
to the ED attendance. Thirty-four percent had a
PaO2 o60mmHg and 18% had a PaCO2 445mmHg
(Table 1).Differences between patients with and
without a diagnosis of COPD
No difference was found in gender, age and severity
of disease between patients with a diagnosis of
COPD prior to the ED attendance and those with-
out. Among patients with a previous diagnosis there
were fewer persistent smokers (34% vs. 60%,
Po0:05) than among those without a diagnosis.
Among these patients there were more subjects
with frequent exacerbations (24% vs. 0%, Po0:01),
more with respiratory failure (34% vs. 12%, Po0:05)
and more with co-morbid conditions (53% vs. 28%,
Po0:05) (Table 1). The mean value of PaO2 was the
only functional parameter which differed signifi-
cantly between the two groups (Table 3).Management prior to the ED attendance
None of the patients who had not been diagnosed as
having COPD prior to the exacerbation had received
any respiratory educational information or regular
treatment; none of the undiagnosed patients
with respiratory failure was on long-term oxygen
therapy.
Among patients with a previous diagnosis of COPD
who were in stage 41, thus requiring regular
treatment according to GOLD guidelines, 21 (25%)
had not received any treatment at all. The
distribution of treatments by stage is shown in
Fig. 2. The percentage of subjects who were not
receiving any regular treatment was remarkably
higher in patients with less severe COPD than in
those with more advanced disease. Among the
patients, 31% and 69% in stages 2 and 3–4,
respectively, were receiving regular treatment with
long-acting inhaled bronchodilators; and 15% and
64% of patients in stages 2 and 3–4, respectively,
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Figure 2 Distribution of treatments in patients diagnosed as having COPD prior to the ED attendance according to GOLD
stage and occurrence of exacerbations.
Table 3 Mean values7SD of lung function and blood gas analysis parameters in the COPD patients with and
without a previous diagnosis.
With previous diagnosis
(n ¼ 85)
Without previous diagnosis
(n ¼ 33)
P
FEV1 (% pred) 55724 55718 NS
FVC (% pred) 77725 78717 NS
FEV1/FVC (%) 54712 54714 NS
PaO2 (mmHg) 63710 7179 o0.001
PaCO2 (mmHg) 4177 3975 NS
M.C. Zoia et al.1572were receiving regular treatment with inhaled
steroids. Ninety-three percent of patients in stage
3–4 with frequent exacerbations were receiving
regular treatment with both long-acting inhaled
bronchodilators and inhaled steroids. Among pa-
tients receiving other treatments–such as mucoly-
tics, antibiotics, and theophylline–only one was
receiving chronic treatment with oral steroids.
Among patients with respiratory failure, 59% were
not receiving long-term oxygen.
None of the patients had participated in a
specific educational program although all had
received some information and advice about smok-
ing cessation. Only 20% had received information on
the nature of the disease and its progression and
none had received a written personal action plan.Discussion
The major results of our study are that: (1) a large
part of patients with moderate-to-very-severeCOPD, some of them already with respiratory
failure, are not diagnosed and treated, and they
get attention through an exacerbation requiring
the ED attendance; (2) the novel approach for the
ongoing pro-active management of the patients
presenting at the ED with an exacerbation allows
one to identify COPD and to minimize the under-
diagnosis and undertreatment within the health
care system.Underdiagnosis
About one-third of patients attending the ED of our
University Hospital because of an exacerbation of
COPD had never been diagnosed prior to the
exacerbation even though a great majority of them
were found on recall to suffer from moderate-to-
very-severe COPD and a substantial part of them
already had respiratory failure.
It is crucial to diagnose and treat COPD even in its
more advanced stages before disability is substan-
tial5 because a variable, yet quite consistent,
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The disease severity does not, by itself, lead more
easily to the diagnosis; in fact, 80% of our patients
without a previous diagnosis were in moderate-to-
very-severe GOLD stages. Our results show that
patients with repeated exacerbations always re-
ceived the diagnosis; they are known to have a
worse health status and more frequently require
medical attention than do those who seldom have
exacerbations.19 Similarly, the presence of co-
morbidity leads more easily to the diagnosis.
Besides physician-related factors, patient-re-
lated factors are also important in explaining
underdiagnosis. Our study shows that underpresen-
tation of symptoms to a physician accounts for
about 50% of missing diagnoses in patients with
moderate-to-very-severe COPD. Remarkably, on
our recall, only 2 patients did not report any
chronic respiratory symptoms when asked specifi-
cally focused questions. So far, education has been
much more actively promoted in asthma than in
COPD20 even if COPD patients are usually older and
frequently less skilful than those with asthma. In
our study, consistent with Gorecka et al.,21 the
awareness of the disease, along with simple advice
about smoking cessation, significantly decreased
the number of active smokers. Unfortunately, we
documented that no patient at all had a written
action plan, and this lack might have played a role
in their utilization of the ED and made the
emergency care more troublesome.Undertreatment
The natural consequence of a missing diagnosis is,
inevitably, no treatment. Moreover, we observed a
considerable percentage of subjects not being
treated even among those with a previous diagnosis
of COPD. A large proportion of our patients
requiring regular treatment with long-acting
bronchodilators according to previous scientific
evidence and to the GOLD guidelines (stage 41)
are not prescribed regular therapy. The long-acting
bronchodilators were, in fact, the most underused
drugs, despite the GOLD guidelines consider, as
’ ’
evidence A’’, bronchodilator medications to be
central to the symptomatic management of
COPD.5,22,23
Almost all our patients in stage 3–4 with
repeated exacerbations had been adequately trea-
ted according to the GOLD guidelines, which
consider inhaled steroids along with long-acting
bronchodilators appropriate for these patients.
More than a half of our patients in stage 3–4
without repeated exacerbations were receiving thesame treatment even though, in this case, inhaled
steroids are not among the recommendations of the
GOLD guidelines. Anyway, the scientific basis of this
approach remains contentious.19,24–26
Remarkably, there was a subgroup of patients
with very severe COPD and respiratory failure who
were not receiving long-term oxygen therapy. This
omission of physicians is particularly culpable
because there has long been clear evidence,
recently reinforced, that long-term administration
of oxygen to patients with chronic respiratory
failure increases survival.26–28Role of exacerbations in COPD management
In recent years COPD exacerbations have received
particular attention and complete agreement has
been achieved on the importance of their preven-
tion and prompt, aggressive treatment.29,30 The
new aspect of our study is that many patients with
moderate-to-very-severe COPD come to attention
through an exacerbation, which can be considered
a failure of COPD treatment. Thus, the ED may
represent not only the setting for mere state-of-
the-art treatment of exacerbation but a valuable
sentinel for identifying this subset of COPD
patients. Even at this time, subsequent interven-
tions in a more appropriate and specialistic setting
are still useful, both for the patient’s personal
health18 and for the society’s health care costs.31,32
Our study documents that this novel approach is
easily feasible within the health care system in all
the patients without a diagnosis of COPD prior to
the ED attendance and in those who are not
adequately treated. It is only required to plan a
follow-up of these patients after the discharge
enhancing a partnership between GPs and specia-
lists by means of a simple letter.Weaknesses of the study
Some questions may be raised about whether our
observations can be generalized. However, we
believe that the present data signal a poor overall
functioning of the care of COPD patients and could
be useful even if they are local. A recent interna-
tional survey estimating the burden of COPD in the
general population showed that the prevalence of
the disease, underdiagnosis and undertreatement
are similar in North America and in many Western
European countries, Italy included.33 The last
available data showed that COPD mortality was
lower in Italy than in the US and similar to that of
many other European countries.34
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recall bias; this is inherent to population studies
using short self-administered questionnaires or
telephone interviews and should be low in our
clinical study although not completely eliminated
because many of our patients were old and/or
poorly skilled. Conscious of this limitation, we
considered only well co-operating patients eligible
for the study. The exclusion of not co-operating
patients, mainly the oldest, may have affected the
results in that the real scenario is even worse than
that we have depicted. Moreover, we cannot
exclude that some patients had earlier
’ ’
declined
treatment offered’’ rather than being
’ ’
missed
from diagnosis’’.
In conclusion, the clinical message of under-
diagnosis and unmet need even in moderate-to-
very-severe COPD and the role of exacerbations as
the starting point of pro-active management are
undoubtably important and should change the
medical practice. Physicians should consider that
an exacerbation of COPD is a failure of manage-
ment of this health problem, provide an analysis of
why earlier diagnosis and treatment has failed or
not been initiated, look for shortcomings in the
system of care as well as in individual compliance,
and initiate pro-active care.References
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